Business
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
Data Accepted as Finalist for First Annual Poster Awards KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a
About this update from Cingulate Inc.
[{"type":"text","content":"Data Accepted as Finalist for First Annual Poster Awards\nKANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced the presentation of full results from the Phase 3 adult efficacy and safety trial of its lead candidate, CTx-1301 (dexmethylphenidate), for the treatment of attention deficit/hyperactivity disorder (ADHD) at the 36th Annual Psych Congress, taking place September 6-10, 2023 in Nashville, TN. The poster was accepted as a finalist for the first annual Psych Congress Poster Awards, which will be awarded onsite at the conference. Poster Awards will be on display on Saturday, September 9, from 6:45-8:15pm CT. “Through our ongoing research, we continue to build evidence on the ability of CTx-1301 to offer patients with ADHD a true, once-daily stimulant medication providing entire active-day efficacy with a rapid onset of action and excellent tolerability,” said Shane J. Schaffer, PharmD, Chairman and CEO, Cingulate. “We believe that the Psych Congress’ selection of our Phase 3 data as a finalist for its first-ever Poster Awards demonstrates the importance of our product’s ability to improve treatment for ADHD.” Ann Childress, M.D., President, Center for Psychiatry and Behavior Medicine, Inc., and lead investigator, will present the full results from the Phase 3 CTx-1301-022 trial. Presentation Details: Poster Title: A Phase 3, Dose-Optimized, Double-Blind, Placebo Controlled, Single-Center, Parallel Efficacy and Safety Laboratory Classroom Study in Adults with Attention Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (dexmethylphenidate)Presenter Name: Ann Childress, M.D.Poster Number: 1596317Date/Time: September 9, 2023, from 6:45-8:00pm CTLocation: Nashville Music City Center in the Karl Dean Ballroom, section A2 CTx-1301 is a novel, investigational treatment being developed as a true, once-daily stimulant medication for ADHD, upon approval from the U.S. Food and Drug Administration (FDA). Last month Cingulate released top-line data from the Phase 3 CTx-1301-022 study (NCT05631626), which assessed efficacy and safety along with onset and duration of CTx-1301 in 21 adults (age range: 18-...